Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.46 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.46 |
| ▸ | CFD | P00746 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.44 |
| ▸ | DNMT3L | Q9UJW3 | 1/20 | 0.44 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33493 | 0.85 | NR1H4 (0.50) | CYP4F2CYP4A11HMGB1CXCL12CFD | |
| SCHEMBL6859574 | 0.84 | KLKB1 (0.62) | HMGB1CXCL12CFDKLKB1CTSB | |
| SCHEMBL11133853 | 0.83 | CYP4F2 (0.51) | CYP4F2CYP4A11HMGB1CXCL12CFD | |
| SCHEMBL5225010 | 0.82 | HMGB1 (0.47) | HMGB1CXCL12CFDKLKB1CTSB | |
| SCHEMBL13652492 | 0.82 | ALDH1A1 (0.50) | HMGB1CXCL12CFDKLKB1CTSB | |
| SCHEMBL2857663 | 0.82 | KLKB1 (0.48) | CYP4F2CYP4A11CFDKLKB1CTSB | |
| SCHEMBL15177931 | 0.81 | KDM4E (0.50) | HMGB1CXCL12KLKB1CTSBMMP9 | |
| SCHEMBL11445335 | 0.81 | HMGB1 (0.46) | HMGB1CXCL12CFDKLKB1CTSB | |
| SCHEMBL19748200 | 0.81 | HMGB1 (0.46) | HMGB1CXCL12CFDKLKB1CTSB | |
| SCHEMBL1671899 | 0.81 | ALDH1A1 (0.47) | HMGB1CXCL12CFDKLKB1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| CN-117700323-A | WO loaded by molecular sieve 3 Catalytic preparation method of bromine-substituted benzoate | 大连金点生物科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117700323-A | WO loaded by molecular sieve 3 Catalytic preparation method of bromine-substituted benzoate | 大连金点生物科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117242073-A | PRMT5 inhibitors and uses thereof | 海思科医药集团股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-104220422-B | EP1 receptors ligands | 埃斯特韦实验室有限公司 | 2017-11-07 | — | — | CN | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| CN-101877966-A | Farnesoid X receptor agonists | SMITHKLINE BEECHAM CORP | 2010-11-03 | — | — | CN | disclosed |
| EP-2173174-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-0777492-B1 | COMBINATORIAL LIBRARIES OF SUBSTRATE-BOUND CYCLIC ORGANIC COMPOUNDS | CHIRON CORP (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-0777492-A4 | COMBINATORIAL LIBRARIES OF SUBSTRATE-BOUND CYCLIC ORGANIC COMPOUNDS | CHIRON CORP (US) | 2002-11-27 | — | — | EP | disclosed |
| US-5958792-A | DERIVATIZING SOLID SUPPORT SURFACES WITH A GROUP CONSISTING OF O AND NH TO PROVIDE PLURALITY OF DERIVATIZED SUPPORT SURFACES, DIVIDING THEM INTO SUBAMOUNTS, REACTING DIFFERENT SUBMONOMER WITH ACTIVE GROUP OF SUBAMOUNT, RECOMBINING | CHIRON CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0777492-A1 | COMBINATORIAL LIBRARIES OF SUBSTRATE-BOUND CYCLIC ORGANIC COMPOUNDS | CHIRON CORPORATION (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996040201-A1 | COMBINATORIAL LIBRARIES OF SUBSTRATE-BOUND CYCLIC ORGANIC COMPOUNDS | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-4448987-A | Catalyzed hydrogenation of terephthalic acid to p-hydroxymethylbenzoic acid using a rhenium catalyst | STANDARD OIL COMPANY (INDIANA) (US) | 1984-05-15 | — | — | US | disclosed |
| US-4130719-A | POLY(METHYLENEBENZOATES | STANDARD OIL COMPANY (INDIANA) (US) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | CYP4F2 105/4885CYP4A11 35/4885HMGB1 2630/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | CYP4F2 3453/4885CYP4A11 1298/4885HMGB1 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.